-
1 Comment
Beijing Aosaikang Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 8.0% below its 200 day moving average.
From a valuation standpoint, the stock is 26.9% cheaper than other stocks from the Industrials sector with a price to sales ratio of 3.7.
Beijing Aosaikang Pharmaceutical Co., Ltd's total revenue rose by 23.3% to $1B since the same quarter in the previous year.
Its net income has increased by 29.0% to $251M since the same quarter in the previous year.
Finally, its free cash flow grew by 600.0% to $192M since the same quarter in the previous year.
Based on the above factors, Beijing Aosaikang Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100001X92 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.39 |
|---|---|
| Market Cap | 18B |
| PE Ratio | 100.72 |
| Target Price | 15 |
| Dividend Yield | None |
Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in digestive, oncology, antibiotic, and other areas. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002755.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
